Issue 5
Nov 2021
Turn off MathJax
Article Contents
SHI Qianling, WANG Zijun, MA Yanfang, WANG Jianjian, LIU Hui, LUO Xufei, YANG Nan, LYU Meng, LIU Yunlan, XUN Yangqin, GUAN Quanlin, CHEN Yaolong. Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019:Funding and Conflicts of Interest[J]. JOURNAL OF MECHANICAL ENGINEERING, 2021, 12(5): 784-790. doi: 10.12290/xhyxzz.2021-0541
Citation: SHI Qianling, WANG Zijun, MA Yanfang, WANG Jianjian, LIU Hui, LUO Xufei, YANG Nan, LYU Meng, LIU Yunlan, XUN Yangqin, GUAN Quanlin, CHEN Yaolong. Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019:Funding and Conflicts of Interest[J]. JOURNAL OF MECHANICAL ENGINEERING, 2021, 12(5): 784-790. doi: 10.12290/xhyxzz.2021-0541

Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019:Funding and Conflicts of Interest

doi: 10.12290/xhyxzz.2021-0541
Funds:

National Social Science Fund of China 19ZDA142

National Key Research and Development Program of China 2018YFC1705500

More Information
  • Corresponding author: GUAN Quanlin  Tel: 86-931-9625222, E-mail: guanquanlin@163.com; CHEN Yaolong  Tel: 86-931-8912639, E-mail: chenyaolong@vip.163.com
  • Received Date: 16 Jul 2021
  • Accepted Date: 03 Sep 2021
  • Available Online: 26 Nov 2021
  • Issue Publish Date: 30 Sep 2021
  •   Objective  To analyze the situation of funding and conflicts of interest of Chinese clinical practice guidelines published in medical journals in 2019, so as to provide reference for the standardized management of funding and conflicts of interest in Chinese guidelines.
      Methods  We systematically searched four electronic databases and additional sources for Chinese guidelines published in medical journals from January 1 to December 31, 2019. After screening, two researchers independently extracted data on funding and conflicts of interest and cross checked. We analyzed data by using EndNote X9, Microsoft Excel 2019 and SPSS 25.0 software.
      Results  We finally included 226 guidelines, of which, 187 were published in Chinese and 39 in English. There were 68 (30.1%) and 120 (53.1%) guidelines that reported funding and conflicts of interest, respectively, and only 41 (18.1%) that reported on both. There were 64 (28.3%) guidelines reported to have received funding, involving 170 projects, which were mainly at the national level (82, 48.2%) and ministerial and provincial-level (52, 30.6%). Only 5 (2.2%) guidelines reported the role of the funder in the stages of the development process. Among the 120 guidelines that reported conflicts of interest, 102 (85.0%) simply described "no conflicts of interest", while there were less than 10% of guidelines that reported the methods of collection, assessment and management for conflicts of interest, and there was no public access available to such information.
      Conclusions  There is a lack of effective management of funding and conflicts of interest in the Chinese guidelines published in medical journals in 2019, which is reflected in the low reporting rate, insufficient reporting contents and unavailable materials provided by the guideline developers. We suggest that guideline developers in the future should pay more attention to the field of guideline funding and conflicts of interest. Guidelines managers and researchers should actively improve management policies, and develop relevant reporting standards.

     

  • loading
  • [1]
    Institute of Medicine (US). Clinical Practice Guidelines We Can Trust[M]. Washington (DC): The National Academies Press, 2011.
    [2]
    Iannone P, Montano N, Minardi M, et al. Wrong guidelines: why and how often they occur[J]. Evid Based Med, 2017, 22: 1-3. doi: 10.1136/ebmed-2016-110606
    [3]
    Holloway RG, Mooney CJ, Getchius TS, et al. Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines[J]. Neurology, 2008, 71: 57-63. doi: 10.1212/01.wnl.0000316319.19159.c3
    [4]
    Saito H, Ozaki A, Sawano T, et al. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan[J]. JAMA Netw Open, 2019, 2: e192834. doi: 10.1001/jamanetworkopen.2019.2834
    [5]
    Checketts JX, Sims MT, Vassar M. Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors[J]. JAMA Dermatol, 2017, 153: 1229-1235. doi: 10.1001/jamadermatol.2017.3109
    [6]
    Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relation-ships from 2004 to 2009 [J]. Arch Intern Med, 2010, 170: 1820-1826. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=55427245&site=ehost-live
    [7]
    Cohen D, Carter P. Conflicts of interest. WHO and the pandemic flu "conspiracies"[J]. BMJ, 2010, 340: c2912. doi: 10.1136/bmj.c2912
    [8]
    Dyer O. WHO retracts opioid guidelines after accepting that industry had an influence[J]. BMJ, 2020, 368: m105. http://bmj.com/content/368/bmj.m105.full
    [9]
    陈耀龙, 王健健, 詹思延, 等. 如何应对指南制订中的利益冲突[J]. 协和医学杂志, 2019, 10: 685-691. doi: 10.3969/j.issn.1674-9081.2019.06.023

    Chen YL, Wang JJ, Zhan SY, et al. How to address conflicts of interest in clinical practice guidelines [J]. Xiehe Yixue Zazhi, 2019, 10: 685-691. doi: 10.3969/j.issn.1674-9081.2019.06.023
    [10]
    Morciano C, Basevi V, Faralli C, et al. Policies on Conflicts of Interest in Health Care Guideline Development: A Cross-Sectional Analysis[J]. PLoS One, 2016, 11: e0166485. doi: 10.1371/journal.pone.0166485
    [11]
    Cosgrove L, Krimsky S, Wheeler EE, et al. Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression[J]. Account Res, 2017, 24: 99-115. doi: 10.1080/08989621.2016.1251319
    [12]
    蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序[J]. 中华医学杂志, 2016, 96: 250-253. doi: 10.3760/cma.j.issn.0376-2491.2016.04.004

    Jiang ZM, Zhan SY, Jia XW, et al. The basic methods and process for developing/revising clinical guidelines [J]. Zhonghua Yixue Zazhi, 2016, 96: 250-253. doi: 10.3760/cma.j.issn.0376-2491.2016.04.004
    [13]
    王强, 黄超, 李俊, 等. 2017年中国发布的临床实践指南中利益冲突与经济学证据的调查分析[J]. 中国循证医学杂志, 2018, 18: 379-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201804019.htm

    Wang Q, Hunag C, Li J, et al. A survey of reporting status of conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2017[J]. Zhongguo Xunzheng Yixue Zazhi, 2018, 18: 379-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201804019.htm
    [14]
    王彦博, 王强, 赵明娟, 等. 2018年中国发布临床实践指南利益冲突与经济学证据的调查分析[J]. 医学新知, 2020, 30: 139-158. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXZ202002009.htm

    Wang YB, Wang Q, Zhao MJ, et al. Conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2018: A survey[J]. Yixue Xinzhi, 2020, 30: 139-158. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXZ202002009.htm
    [15]
    Gao YT, Wang JJ, Luo XF, et al. Quality appraisal of clinical practice guidelines for diabetes mellitus published in China between 2007 and 2017 using the AGREE Ⅱ instrument [J]. BMJ Open, 2019, 9: e022392. doi: 10.1136/bmjopen-2018-022392
    [16]
    杨钦博, 周奇, 黄天相, 等. 2017年中国大陆期刊发表的临床实践指南的报告质量评价[J]. 中国循证医学杂志, 2019, 19: 1325-1332. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201911011.htm

    Yang QB, Zhou Q, Huang TX, et al. Reporting quality of clinical practice guidelines published in journals of mainland China in 2017[J]. Zhongguo Xunzheng Yixue Zazhi, 2019, 19: 1325-1332. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201911011.htm
    [17]
    Wang XQ, Chen YL, Yao L, et al. Reporting of declarations and conflicts of interest in WHO guidelines can be further improved[J]. J Clin Epidemiol, 2018, 98: 1-8. doi: 10.1016/j.jclinepi.2017.12.021
    [18]
    王子君, 史乾灵, 刘云兰, 等. 2019年期刊公开发表的中国临床实践指南文献调查与评价——制订人员及工作组情况[J]. 协和医学杂志, 2021, 12: 552-559. doi: 10.12290/xhyxzz.2021-0438

    Wang ZJ, Shi QL, Liu YL, et al. Investigation and Evaluation of China Clinical Practice Guidelines Published in Medical Journals in 2019——Basic Information and Status of the Authorship and Guideline Development Group[J]. Xiehe Yixue Zazhi, 2021, 12: 552-559. doi: 10.12290/xhyxzz.2021-0438
    [19]
    Chen YL, Yang KH, Marušic A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J]. Ann Intern Med, 2017, 166: 128-132. doi: 10.7326/M16-1565
    [20]
    Moynihan R, Lai A, Jarvis H, et al. Undisclosed financial ties between guideline writers and pharmaceutical comp-anies: a cross-sectional study across 10 disease categories[J]. BMJ Open, 2019, 9: e025864. doi: 10.1136/bmjopen-2018-025864
    [21]
    Guyatt G, Akl EA, Hirsh J, et al. The vexing problem of guidelines and conflict of interest: a potential solution[J]. Ann Intern Med, 2010, 152: 738-741. doi: 10.7326/0003-4819-152-11-201006010-00254
    [22]
    Nejstgaard CH, Bero L, Hróbjartsson A, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review[J]. BMJ, 2020, 371: m4234. http://www.bmj.com/content/371/bmj.m4234.short
    [23]
    Vassar M, Bibens M, Wayant C. Transparency of industry payments needed in clinical practice guidelines[J]. BMJ Evid Based Med, 2019, 24: 8-9. doi: 10.1136/bmjebm-2018-111020
    [24]
    张以芳. 医学编辑对临床实践指南的审理要点探讨[J]. 编辑学报, 2020, 32: 627-631. https://www.cnki.com.cn/Article/CJFDTOTAL-BJXB202006012.htm

    Zhang YF. Key points in reviewing clinical practice guidelines for medical editors[J]. Bianji Xuebao, 2020, 32: 627-631. https://www.cnki.com.cn/Article/CJFDTOTAL-BJXB202006012.htm
  • 加载中

Catalog

    Tables(3)

    Article Metrics

    Article views(205) PDF downloads(0) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return